Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis
- 21 November 2016
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 47 (1) , 7-18
Abstract
Background: Chemerin is associated with insulin resistance and is expressed in the liver. Nonalcoholic fatty liver disease (NAFLD) is related to impaired insulin sensitivity, but studies evaluating hepatic and serum chemerin in NAFLD resulted in discordant data.Materials and methods: Chemerin mRNA was determined in the liver tissue obtained from 33 controls and 76 NAFLD patients. Chemerin serum levels were measured in a different cohort of patients with ultrasound‐diagnosed NAFLD and the respective controls. Hepatic stellate cells and hepatocytes were exposed to selected metabolites and nuclear receptor agonists to study the regulation of chemerin. Effect of recombinant chemerin on hepatocyte released proteins was analysed.Results: Hepatic chemerin expression was not related to BMI, gender, type 2 diabetes and hypertension. Chemerin mRNA did not correlate with steatosis and was negatively associated with inflammation, fibrosis and nonalcoholic steatohepatitis (NASH) score. Patients with NASH had lower chemerin mRNA compared to those with borderline NASH and controls. Factors with a role in NASH mostly did not regulate chemerin in the liver cells. Of note, liver X receptor agonist reduced chemerin protein. Serum chemerin was not changed in NAFLD. Levels positively correlated with age, waist‐to‐hip ratio, systolic blood pressure, serum FGF21 and lipocalin 2, and negatively with transferrin saturation. Chemerin induced FGF21 in supernatants of primary human hepatocytes. Hepcidin, a major regulator of iron homoeostasis and lipocalin 2, were not regulated by chemerin.Conclusion: Chemerin mRNA is reduced in the liver of NASH patients, and liver X receptor seems to have a role herein.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (BU 1141/7‐1)
This publication has 49 references indexed in Scilit:
- Towards an integrative approach to understanding the role of chemerin in human health and diseaseObesity Reviews, 2012
- NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic ImplicationsGut and Liver, 2012
- Soluble CD163 is not increased in visceral fat and steatotic liver and is even suppressed by free fatty acids in vitroExperimental and Molecular Pathology, 2011
- Chemerin: at the crossroads of inflammation and obesityTrends in Endocrinology & Metabolism, 2010
- Expression of Human Chemerin Induces Insulin Resistance in the Skeletal Muscle but Does Not Affect Weight, Lipid Levels, and Atherosclerosis in LDL Receptor Knockout Mice on High-Fat DietDiabetes, 2010
- Chemerin Is a Novel Adipocyte-Derived Factor Inducing Insulin Resistance in Primary Human Skeletal Muscle CellsDiabetes, 2009
- Insulin and Metformin Regulate Circulating and Adipose Tissue ChemerinDiabetes, 2009
- Adipocytokines and liver diseaseJournal of Gastroenterology, 2008
- Synthetic chemerin-derived peptides suppress inflammation through ChemR23Journal of Experimental Medicine, 2008
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005